DK4358995T3 - Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser - Google Patents

Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser

Info

Publication number
DK4358995T3
DK4358995T3 DK22744054.2T DK22744054T DK4358995T3 DK 4358995 T3 DK4358995 T3 DK 4358995T3 DK 22744054 T DK22744054 T DK 22744054T DK 4358995 T3 DK4358995 T3 DK 4358995T3
Authority
DK
Denmark
Prior art keywords
glp
treatment
combination
pathway
metabolic disorders
Prior art date
Application number
DK22744054.2T
Other languages
English (en)
Inventor
Kimberly Long
Yung Chyung
George Nomikos
Jeffrey S Flier
Micah T Webster
Christopher Chapron
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=82608742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4358995(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Application granted granted Critical
Publication of DK4358995T3 publication Critical patent/DK4358995T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK22744054.2T 2021-06-23 2022-06-22 Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser DK4358995T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163214234P 2021-06-23 2021-06-23
US202163260136P 2021-08-10 2021-08-10
US202163260254P 2021-08-13 2021-08-13
US202263266348P 2022-01-03 2022-01-03
US202263269702P 2022-03-21 2022-03-21
PCT/US2022/034588 WO2022271867A1 (en) 2021-06-23 2022-06-22 A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders

Publications (1)

Publication Number Publication Date
DK4358995T3 true DK4358995T3 (da) 2026-02-02

Family

ID=82608742

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22744054.2T DK4358995T3 (da) 2021-06-23 2022-06-22 Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser

Country Status (15)

Country Link
US (1) US20240368262A1 (da)
EP (2) EP4714494A3 (da)
JP (1) JP2024524159A (da)
AU (1) AU2022299185A1 (da)
CA (1) CA3221555A1 (da)
DK (1) DK4358995T3 (da)
ES (1) ES3062188T3 (da)
FI (1) FI4358995T3 (da)
IL (1) IL309078A (da)
MX (1) MX2023014840A (da)
PL (1) PL4358995T3 (da)
PT (1) PT4358995T (da)
SI (1) SI4358995T1 (da)
TW (1) TW202317175A (da)
WO (1) WO2022271867A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
JP2025532651A (ja) * 2022-09-21 2025-10-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 肥満、糖尿病および肝機能障害を処置する方法
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
IL326224A (en) * 2023-07-31 2026-03-01 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025219859A1 (en) * 2024-04-14 2025-10-23 Biohaven Therapeutics Ltd. Combination therapy to treat overweight, obesity, and related health conditions
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
WO2025245160A1 (en) 2024-05-21 2025-11-27 Scholar Rock, Inc. Myostatin-selective inhibitors for treating metabolic disorders
WO2026037938A1 (en) * 2024-08-16 2026-02-19 Protuoso Pte. Ltd. Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor
WO2026090182A1 (en) * 2024-10-23 2026-04-30 Emmyon, Inc. Glp-1 receptor agonist and ursolic acid combinations and use thereof for increasing weight loss while improving muscle mass and strength

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
EA201891420A1 (ru) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PL4218804T3 (pl) 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
HRP20230308T1 (hr) * 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
US20210087250A1 (en) * 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
SG11202108099WA (en) * 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF

Also Published As

Publication number Publication date
US20240368262A1 (en) 2024-11-07
WO2022271867A1 (en) 2022-12-29
EP4358995A1 (en) 2024-05-01
ES3062188T3 (en) 2026-04-09
FI4358995T3 (fi) 2026-02-04
PT4358995T (pt) 2026-02-17
AU2022299185A1 (en) 2024-01-25
MX2023014840A (es) 2024-02-12
EP4714494A3 (en) 2026-04-22
PL4358995T3 (pl) 2026-04-20
TW202317175A (zh) 2023-05-01
JP2024524159A (ja) 2024-07-05
IL309078A (en) 2024-02-01
EP4714494A2 (en) 2026-03-25
SI4358995T1 (sl) 2026-03-31
CA3221555A1 (en) 2022-12-29
EP4358995B1 (en) 2025-12-03

Similar Documents

Publication Publication Date Title
SI4358995T1 (sl) Zaviralec miostatinske poti v kombinaciji z aktivatorjem poti glp-1 za uporabo pri zdravljenju presnovnih motenj
DK2420234T3 (da) 1H-benzimidazol-4-carboxamider substitueret med et kvaternært carbon i 2-stillingen som PARP-inhibitorer til anvendelse ved behandling af cancer
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
CL2008000089A1 (es) Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios.
MX386826B (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística
MX2009010946A (es) Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
DK2323642T3 (da) Anvendelse af EDTA+tromethamin eller af fotoforstærkere i forbindelse med riboflavin til hornhindetværbinding ved behandling af keratoconus eller af andre ektatiske hornhindelidelser
UY32380A (es) Combinaciones que comprenden metotrexato e inhibidores de dhodh
NI200900205A (es) Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c.
CO6321290A2 (es) Nuevos inhibidores macrociclicos basados en pirrolidinilo de la replicacion de virus de la hepatitis c
CL2012002528A1 (es) Combinacion farmaceutica que comprende un inhibidor de dpp iv de formula i definida y metamorfina, o una glitazona o tiazolidindiona, o telmisartan; util en el tratamiento de diabetes (divisonal sol 1262-07).
DK2125004T3 (da) Synergistisk terapeutisk anvendelse af prothrombinkompleks koncentrater med fviii koncentrater
DK2694072T4 (da) Kombination af AKT-inhibitor-forbindelse og abirateron til anvendelse i terapeutiske behandlinger
DK4076461T3 (da) Lumateperon til brug ved behandling af skizofreni
DK2307035T3 (da) Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
AR082660A1 (es) Composiciones farmaceuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CL2022001357A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
DK4161528T3 (da) Kombination af ruxolitinib med incb057643 til anvendelse ved behandling af myeloproliferative neoplasmer
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
UY34408A (es) Nuevos moduladores de trpv3
DK4419526T3 (da) Heterocykliske forbindelser til anvendelse i behandlingen af cancer
DK4518970T3 (da) Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi
EP2792357A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF THROMBOEMBOLY FOR THROMBOEMBLE PATIENTS WITH HEAVY KIDNEY FUNCTION TROUBLESHOOTING
UY31824A (es) Nuevos compuestos
DK3773615T3 (da) Flydende sammensætning til anvendelse ved behandling af slimhinden i munden-svælget-struben-spiserøret